What Is ARKG? ARK Genomic Revolution ETF
Short answer
ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like CRISPR Therapeutics, Tempus AI, Twist Bioscience, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly 60% of assets. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion. It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.
ARKG is issued by ARK Invest and tracks Actively managed (no index); focused on genomics and biotech innovation. It charges a 0.75% expense ratio, holds approximately approximately $1.2 billion in assets under management, yields about 0.00% (does not currently pay a dividend), and launched in October 31, 2014.
What is ARKG?
ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like CRISPR Therapeutics, Tempus AI, Twist Bioscience, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly 60% of assets. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion. It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.
ARKG is issued by ARK Invest and tracks Actively managed (no index); focused on genomics and biotech innovation, so a single ticker gives you the whole basket of underlying holdings weighted by the index's methodology rather than by any active stock-picking.
ARKG holdings: what's actually inside
ARKG is weighted toward its largest constituents. As of early 2026, the top holdings are:
| Rank | Ticker | Company | % of ARKG | |
|---|---|---|---|---|
| 1 | TWST | Twist Bioscience Corp. | 9.2% | |
| 2 | TEM | Tempus AI Inc. | 7.6% | |
| 3 | TXG | 10x Genomics Inc. | 6.9% | |
| 4 | CRSP | CRISPR Therapeutics AG | 6.8% | |
| 5 | ABSI | Absci Corp. | 6.7% | |
| 6 | BEAM | Beam Therapeutics Inc. | approximately 5% | |
| 7 | NTLA | Intellia Therapeutics Inc. | approximately 5% | |
| 8 | RXRX | Recursion Pharmaceuticals Inc. | approximately 4% | |
| 9 | PACB | Pacific Biosciences of California Inc. | approximately 4% | |
| 10 | SDGR | Schrodinger Inc. | approximately 4% |
The remaining holdings make up the balance of the fund, with weights tapering off below the top names. Because the index reconstitutes on a rolling basis, the roster stays current without active management. Each ticker above links to its individual stock guide in Walnut.
The bottom line on ARKG
ARKG offers concentrated, actively-managed exposure to genomics and gene-editing innovation, but it is highly volatile and dominated by speculative, often pre-profit biotech names. It has experienced a severe drawdown since its early-2021 peak, so it suits only investors comfortable with sharp swings and the risk of large, prolonged losses.
More on ARKG
Whether ARKG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is ARKG a buy?
ARKG yields 0.00% (does not currently pay a dividend) as of early 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see ARKG dividend: yield and schedule.
Build a portfolio around ARKG with Walnut
Use ARKG as your core holding, then let Walnut's AI propose thematic satellites: AI infrastructure, dividend growth, clean energy, whatever you believe in. Connect your broker, build the basket in conversation, track it as one unit.
FAQ
What is ARKG?
+
ARKG is the ARK Genomic Revolution ETF, an actively-managed fund from Cathie Wood's ARK Invest. It invests in companies tied to the genomics revolution, including gene editing, molecular diagnostics, biotechnology, and AI-driven drug discovery, holding names like CRISPR Therapeutics, Tempus AI, and Twist Bioscience.
What is ARKG's expense ratio?
+
ARKG has an expense ratio of 0.75%, which means about $7.50 in annual fees per $1,000 invested. That is high relative to passive index ETFs but typical for an actively-managed thematic fund.
Is ARKG actively managed?
+
Yes. ARKG is actively managed by ARK Invest and does not track an index. The management team selects and weights holdings based on its own research into genomics and biotech innovation, so the portfolio changes over time as ARK's convictions shift.
What does ARKG hold?
+
ARKG holds a concentrated portfolio of roughly 30 to 35 genomics and biotech-innovation stocks. Top holdings as of early 2026 include Twist Bioscience, Tempus AI, 10x Genomics, CRISPR Therapeutics, and Absci, with the top 10 making up around 60% of assets. Many holdings are early-stage, pre-profit biotech companies.
Does ARKG pay a dividend?
+
ARKG does not currently pay a meaningful dividend; its yield is effectively 0%. Most of its holdings are growth-oriented, often unprofitable biotech companies that reinvest rather than pay dividends, so ARKG is not an income-focused fund.
Is ARKG a good investment?
+
Whether ARKG fits a portfolio depends on your goals, risk tolerance, and time horizon. It is a high-risk, very volatile thematic fund that has had a large drawdown since 2021. Walnut is informational, not investment advice, so consider doing your own research or consulting a licensed financial professional.
How volatile is ARKG and how big has its drawdown been?
+
ARKG is extremely volatile because it concentrates in speculative, often pre-profit biotech and gene-editing stocks. Since its early-2021 peak it has fallen dramatically, with assets dropping from roughly $9 billion to about $1.2 billion by early 2026, reflecting a deep and prolonged drawdown that investors should expect could repeat.
How concentrated is ARKG?
+
ARKG is highly concentrated for an ETF, holding only about 30 to 35 positions with the top 10 accounting for roughly 60% of assets. Single names such as Twist Bioscience and Tempus AI can each represent 7% to 9% of the fund, so company-specific news can move ARKG sharply.
How do I compare ARKG to similar ETFs?
+
Put a few fields side by side: the expense ratio (fees compound over decades), the index or strategy it tracks, the top holdings and how much they overlap with what you already own, the dividend yield, and the AUM, liquidity, and bid-ask spread that affect trading costs. For index funds, tracking error (how closely it follows its index) and tax efficiency matter too. ARKG's figures are above; the full method is in Walnut's guide on how to compare ETFs.
Related ETFs
Walnut is informational, not investment advice. Holdings weights and fund statistics on this page are approximations stamped to early 2026; verify current figures against ARK Invest's fund page or your broker before investing.